The Antimicrobial Activities of Trimethoprim and Sulfonamides

References

• Roth B, Falco E A, Hitchings G H, Bushby S RM. 5-benzyl-2, 4-diaminopyrimidines as antibacterial agents. I. Synthesis and antibacterial effect in vitro. J Med Pharm Chem 1962; 5: 1103–1123
   Google Scholar
• Burman L G. Significance of the sulfonamide component for the clinical efficacy of trimethoprim-sulfonamide combination. Scand J Infect Dis 1986; 18
   Google Scholar
• Woods D D. The relation of p-aminobenzoic acid to the mechanism of the action of sulphanilamide. Br J Exp Pathol 1940; 21: 74–90
   Google Scholar
• Hitchings G H. Mechanism of action of trimethoprim-sulfamethoxazole. I. J Infect Dis 1973; 128: 433–436, Suppl
   Google Scholar
• Burchall J J. Mechanism of action of trimethoprim-sulfamethoxazole. II. J Infect Dis 1973; 128: 437–441, Suppl
   Google Scholar
• Averett D R, Roth B, Burchall J J, Baccanari D P. Dihydrofolate reductase from Neisseria sp. Antimicrob Agents Chemother 1979; 15: 428–435
   PubMedGoogle Scholar
• Then R L. Neisseriaceae, a group of bacteria with dihydrofolate reductases, moderately susceptible to trimethoprim. Zentralbl Bakteriol [Orig A] 1979; 245: 450–458
   PubMedGoogle Scholar
• Then R L, Angehrn P. Low trimethoprim susceptibility of anaerobic bacteria due to insensitive dihydrofolate reductases. Antimicrob Agents Chemother 1979; 15: 1–6
   PubMedGoogle Scholar
• Grunberg E, Prince H N, De Lorenzo W F. The in vivo effect of folinic acid (citrovorum factor) on the potentiation of the antibacterial activity of sulfisoxazole by trimethoprim. J Clin Pharmacol 1970; 10: 231–234
   Google Scholar
• Jenkins G C, Hughes D TD, Hall P C. A haematological study of patients receiving long-term treatment with trimethoprim and sulphonamide. J Clin Pathol 1970; 23: 392–396
   PubMed Web of Science ®Google Scholar
• Kahn S B, Fein S A, Brodsky I. Effects of trimethoprim on folate metabolism in man. Clin Pharmacol Ther 1968; 9: 550–555
   PubMed Web of Science ®Google Scholar
• Harvey R J. Synergism in the folate pathway. Rev Infect Dis 1982; 4: 255–260
   PubMedGoogle Scholar
• Poe M. Antibacterial synergism: A proposal for chemotherapeutic potentiation between trimethoprim and sulfamethoxazole. Science 1976; 194: 533–535
   PubMedGoogle Scholar
• Burchall J J, Then R. Synergism between trimethoprim and sulfamethoxazole. Science 1977; 197: 1300–1301
   Google Scholar
• Lacey R W. Mechanism of action of trimethoprim and sulphonamides: relevance to synergy in vivo. J Antimicrob Chemother 1979; 5: 75–83, Suppl B
   PubMedGoogle Scholar
• Baccanari D P, Joyner S S. Dihydrofolate reductase hysteresis and its effect on inhibitor binding analyses. Biochemistry 1981; 20: 1710–1716
   PubMedGoogle Scholar
• Amyes S GB, Smith J T. Trimethoprim action and its analogy with thymine starvation. Antimicrob Agents Chemother 1974; 5: 169–178
   PubMedGoogle Scholar
• Then R, Angehrn P. Nature of the bactericidal action of sulfonamides and trimethoprim, alone and in combination. J Infect Dis 1973; 128: 498–501, Suppl
   Google Scholar
• Amyes S GB. Bactericidal activity of trimethoprim alone and in combination with sulfamethoxazole on susceptible and resistant Escherichia coli K-12. Antimicrob Agents Chemother 1982; 21: 288–293
   PubMed Web of Science ®Google Scholar
• Waterworth P M. Sulphonamides and trimethoprim. Laboratory methods in antimicrobial chemotherapy, D S Reeves, I Phillips, D J Williams, R Wise. Churchill Livingstone, London 1978; 82–84
   Google Scholar
• Wormser G P, Keusch G T, Heel R C. Co-trimoxazole (trimethoprim-sulfamethoxazole). An updated review of its antibacterial activity and clinical efficacy. Drugs 1982; 24: 459–518
   PubMed Web of Science ®Google Scholar
• Phillips I, Warren C. Susceptibility of Bacteroides fragilis to trimethoprim and sulphamethoxazole. Lancet 1974; 1: 827–829
   PubMedGoogle Scholar
• Phillips I, Warren C. Activity of sulfamethoxazole and trimethoprim against Bacteroides fragilis. Antimicrob Agents Chemother 1976; 9: 736–740
   PubMedGoogle Scholar
• Bach M C, Finland M, Gold O, Wilcox C. Susceptibility of recently isolated pathogenic bacteria to trimethoprim and sulfamethoxazole separately and combined. J Infect Dis 1973; 128: 508–533, Suppl
   Google Scholar
• Bushby S RM. Trimethoprim-sulfamethoxazole: In vitro microbiological aspects. J Infect Dis 1973; 128: 442–462, Suppl
   Web of Science ®Google Scholar
• Kucers A, McBennett K N. Trimethoprim and co-trimoxazole. The use of antibiotics, a comprehensive review with clinical emphasis. W Heinemann Medical Books Ltd, London 1979; 687–728
   Google Scholar
• Lorian V. Antibiotics in laboratory medicine. William & Wilkins, Baltimore, London 1980
   Google Scholar
• Rein M F, Elliott W C, Swenson J M, Thornsberry C. Sulfamethoxazole-trimethoprim synergism for Neisseria gonorrhoeae. Antimicrob Agents Chemother 1980; 17: 247–250
   PubMedGoogle Scholar
• Kamme C, Melander A, Nilsson N-I. Serum and saliva concentrations of sulfamethoxazole and trimethoprim in adults and children: Relation between saliva concentrations and in vitro acitivity against nasopharyngeal pathogens. Scand J Infect Dis 1983; 15: 107–113
   PubMed Web of Science ®Google Scholar
• Löfgren S. 1984, Personal communication
   Google Scholar
• Gutman L T, Wilfert C M, Quan T. Susceptibility of Yersinia enterocolitica to trimethoprim-sulfamethoxazole. J Infect Dis 1973; 128: 538, Suppl
   Google Scholar
• Vanhoof R, Gordts B, Dierickx R, Coignau H, Butzler J P. Bacteriostatic and bactericidal activities of 24 antimicrobial agents against Campylobacter. Antimicrob Agents Chemother 1980; 18: 118–121
   PubMedGoogle Scholar
• Svedhem Å, Kaijser B, Sjögren E. Antimicrobial susceptibility of Campylobacter jejuni isolated from humans with diarrhoea and from healthy chickens. J Antimicrob Chemother 1981; 7: 301–305
   PubMed Web of Science ®Google Scholar
• Jackson-York G L, Gump B B, Gump D W. Activity of trimethoprim (TMP), sulphamethoxazole (SMX) and the combintion against Bacteroides fragilis group isolates. J Antimicrob Chemother 1983; 12: 515–518
   PubMedGoogle Scholar
• Ridgway G L, Own J M, Oriel J D. The antimicrobial susceptibility of Chlamydia trachomatis in cell culture. Br J Vener Dis 1978; 54: 103–106
   PubMedGoogle Scholar
• Hammerschlag M R. Activity of trimethoprim-sulfamethoxazole against Chlamydia trachomatis in vitro. Rev Infect Dis 1982; 4: 500–505
   PubMedGoogle Scholar
• Edelstein P H, Meyer R D. Susceptibility of Legionella pneumophila to twenty antimicrobial agents. Antimicrob Agents Chemother 1980; 18: 403–408
   PubMed Web of Science ®Google Scholar
• Thornsberry C, McDougal L. In vitro susceptibility of Legionella species to antimicrobial agents. Current chemotherapy and immunotherapy. Proceedings of the 12th international congress of chemotherapy, P Periti, G G Grassi. The American Society for Microbiology, Washington 1981; 24–26
   Google Scholar
• Wallace R J, Jr, Wiss K, Buchby M B, Hollowell D C. In vitro activity of trimethoprim and sulfamethoxazole against the nontuberculous mycobacteria. Rev Infect Dis 1982; 4: 326–331
   PubMedGoogle Scholar
• Salter A J. Trimethoprim-sulfamethoxazole for serious infections. Rev Infect Dis 1982; 4: 338–350
   PubMedGoogle Scholar
• Dornbusch K. Regression line analysis of the synergistic effect for the combination of trimethoprim/sulphamethoxazole. Chemotherapy 1971; 17: 229–238
   Google Scholar
• Grace M E, Bushby S RM, Siegel C W. Diffusion of trimethoprim and sulphamethoxazole from susceptibility discs into agar. Antimicrob Agents Chemother 1975; 8: 45–48
   PubMedGoogle Scholar
• Bushby S RM, Hitchings G H. Trimethoprim, a sulphonamide potentiator. Br J Pharmacol 1968; 33: 72–90
   PubMed Web of Science ®Google Scholar
• Japan cooperative bacteriological study group for co-trimoxazole. Analysis of in vitro antibacterial activities of the combination of trimethoprim and sulfamethoxazole on clinical isolates in Japan. J Infect Dis 1973; 128: 502–507, Suppl
   Web of Science ®Google Scholar
• Bushby S RM, Barnett M. Trimethoprim-sulphonamides—in vitro sensitivity of 384 strains of bacteria. Proc 5th Int Congr Chemotherapy. Vienna 1967; 753–757
   Google Scholar
• Acar J F, Goldstein F, Chabbert Y A. Synergistic activity of trimethoprim-sulfamethoxazole on gram-negative bacilli: Observations in vitro and in vivo. J Infect Dis 1973; 128: 470–477, Suppl
   Google Scholar
• Grüneberg R N. The use of co-trimoxazole in sulphonamide-resistant Escherichia coli urinary tract infection. J Antimicrob Chemother 1975; 1: 305–310
   PubMedGoogle Scholar
• Grey D, Hamilton-Miller J MT. Sensitivity of Pseudomonas aeruginosa to sulphonamides and trimethoprim and the activity of the combination trimethoprim-sulphamethoxazole. J Med Microbiol 1977; 10: 273–279
   PubMedGoogle Scholar
• Grey D, Hamilton-Miller J MT, Brumfitt W. Combined action of sulphamethoxazole and trimethoprim against clinically isolated sulphonamide-resistant bacteria. Chemotherapy 1979; 25: 296–302
   PubMedGoogle Scholar
• Schmidt U, Sen P, Kapila R, Louria D B. Clinical evaluation of intravenous trimethoprim-sulfamethoxazole for serious infections. Rev Infect Dis 1982; 4: 332–337
   PubMedGoogle Scholar
• Grose W E, Bodey G P, Loo T L. Clinical pharmacology of intravenously administered trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 1979; 15: 447–451
   PubMedGoogle Scholar